Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System
- 7 November 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 8 (45) , 30703-30713
Abstract
Diabetes, a global epidemic, has become a serious threat to public health. The present study is aimed at constructing an injectable thermosensitive PEG–polyester hydrogel formulation of liraglutide (Lira), a “smart” antidiabetic polypeptide, in the long-acting treatment of type 2 diabetes mellitus. A total of three thermosensitive poly(ε-caprolactone-co-glycolic acid)-poly(ethylene glycol)-poly(ε-caprolactone-co-glycolic acid) (PCGA–PEG–PCGA) triblock copolymers with similar molecular weights but different ε-caprolactone-to-glycolide (CL-to-GA) ratios were synthesized. The polymer aqueous solutions exhibited free-flowing sols at room temperature and formed in situ hydrogels at body temperature. While the different bulk morphologies, stabilities of aqueous solutions, and the varying in vivo persistence time of hydrogels in ICR mice were found among the three copolymers, all of the Lira-loaded gel formulations exhibited a sustained drug release manner in vitro regardless of CL-to-GA ratios. The specimen with a powder form in the bulk state, a stable aqueous solution before heating, and an appropriate degradation rate in vivo was selected as the optimal carrier to evaluate the in vivo efficacy. A single injection of the optimal gel formulation showed a remarkable hypoglycemic efficacy up to 1 week in diabetic db/db mice. Furthermore, three successive administrations of this gel formulation within one month significantly lowered glycosylated hemoglobin and protected islets of db/db mice. As a result, a promising once-weekly delivery system of Lira was developed, which not only afforded long-term glycemic control but also significantly improved patient compliance.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2015AA033703)
- National Natural Science Foundation of China (21474019, 51273217)
- Science and Technology Developing Foundation of Shanghai (14441901500, 15JC1490300)
- State Key Project of Research and Development (2016YFC1100300)
This publication has 59 references indexed in Scilit:
- Recent advances in incretin‐based therapiesClinical Endocrinology, 2012
- Review of the Therapeutic Uses of LiraglutideClinical Therapeutics, 2011
- Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetesBiomaterials, 2011
- Glycaemic control in type 2 diabetes: Targets and new therapiesPharmacology & Therapeutics, 2010
- A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitusClinical Therapeutics, 2009
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- Mechanisms of action of glucagon-like peptide 1 in the pancreasPharmacology & Therapeutics, 2007
- Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitusExpert Opinion on Investigational Drugs, 2007
- Glucagon-like peptide 1 and its derivatives in the treatment of diabetesRegulatory Peptides, 2005
- Therapeutic Strategies Based on Glucagon-Like Peptide 1Diabetes, 2004